Reata Pharmaceuticals, Inc.
1950 Stemmons Freeway, Suite 5001
Dallas
Texas
75207
United States
Tel: 214-800-8700
Fax: 214-722-0867
Website: http://www.reatapharma.com/
Email: info@reatapharma.com
105 articles with Reata Pharmaceuticals, Inc.
-
Reata Provides Update on Omaveloxolone Program for Patients with Friedreich’s Ataxia
11/24/2020
Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration completed its internal review of the Baseline-Controlled Study results of omaveloxolone for the treatment of patients with Friedreich’s ataxia and concluded that the results do not strengthen the results of Part 2 of the MOXIe study.
-
Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs
11/9/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended September 30, 2020, and provided an update on the Company’s business operations and clinical development programs.
-
Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
11/9/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Phase 3 CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome met its primary and key secondary endpoints at the end of Year 2.
-
Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020
11/2/2020
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on its development programs before the market opens on November 9, 2020.
-
Reata Pharmaceuticals, Inc. Announces Presentation of KIDNEYCODE Program at the American Society of Nephrology Kidney Week 2020 Reimagined
10/15/2020
Reata Pharmaceuticals, Inc. announced the upcoming presentation of KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease, as an e-poster to be presented at the American Society of Nephrology Kidney Week 2020 Reimagined.
-
Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich’s Ataxia at the American Academy of Neurology
9/3/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the forthcoming presentation of efficacy and safety results from the pivotal MOXIe Part 2 study, a randomized, double-blind, placebo-controlled trial of omaveloxolone in Friedreich’s ataxia.
-
Texas-based Reata Pharmaceuticals announced the potential delay Monday when it released its 2nd quarter financial report.
-
Reata Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs
8/10/2020
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended June 30, 2020, and provided an update on the Company’s
-
Reata Pharmaceuticals, Inc. to Report Second Quarter 2020 Financial Results and to Provide an Update on Development Programs on August 10, 2020
8/3/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will report financial results and provide an update on its development programs pre-market on August 10, 2020.
-
Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors
7/30/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Martin W. Edwards, M.D. to its Board of Directors, effective August 3, 2020.
-
Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19
7/28/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that researchers at NYU Grossman School of Medicine, led by Sripal Bangalore, MD, interventional cardiologist and professor of Medicine, are initiating an Investigator-Sponsored Trial, known as BARCONA, to study the effect of bardoxolone methyl in patients suffering from COVID-19.
-
Blackstone Announces $4.6 Billion Final Close of Life Sciences Fund
7/9/2020
Blackstone Life Sciences has already invested and committed nearly $1 billion from this fund over the past three months, demonstrating strong demand for the strategy
-
Reata Announces Promotion and New Hires For Key Leadership Roles
7/7/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the expansion of its leadership team and the appointment of several experienced industry leaders to key management roles.
-
Reata Pharmaceuticals, Inc. Closes $350 Million Strategic Investment From Blackstone Life Sciences
6/24/2020
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the receipt of $350 million related to the closing of its previously announced strategic investment from funds managed by Blackstone Life Sciences. This financing includes $300 million in return for single-digit royalty payments on worldwide net sales of bardoxolone methyl (“bardoxolone”) by Reata and its licensees,
-
Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment
6/11/2020
FINANCING WILL ADVANCE BARDOXOLONE AS THE FIRST POTENTIAL THERAPY FOR ALPORT SYNDROME, AS WELL AS CONTINUE DEVELOPMENT FOR OTHER RARE AND SERIOUS FORMS OF CHRONIC KIDNEY DISEASE REATA’S CASH GUIDANCE UPDATED: RUNWAY EXTENDED THROUGH END OF 2023 REATA TO HOST CONFERENCE CALL ON JUNE 11, 2020 AT 8:30 AM ET NEW YORK and PLANO, Texas, June 11, 2020 (GLOBE NEWSWIRE) -- Blackstone (NYSE: BX) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata”), a clinical-stage biopharmaceutical co
-
Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs
5/11/2020
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended March 31, 2020, and provided an update on the Company’s business and product development programs.
-
Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020
5/4/2020
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs post-market on May 11, 2020.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Reata Pharma Updates Business Operations and Clinical Trials in Light of COVID-19 Pandemic
3/31/2020
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment," said Warren Huff, Reata’... -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.